Guess which ASX All Ords insider just bought 50 million shares in their company

Some major insider buying has taken place. What does this mean?

| More on:
A man in a business suit whose face isn't shown hands over two australian hundred dollar notes from a pile of notes in his other hand to an outstretched hand of another person.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It can be useful for investors to keep an eye on which shares have experienced meaningful insider buying.

This is because insider buying is often regarded as a bullish indicator, as few people know a company and its intrinsic value better than its directors.

If they are buying, it could be a sign that they are confident in the direction the company is heading and see value in its shares.

With that in mind, let's take a look at one ASX All Ords stock that has reported some major insider buying this week.

Which ASX All Ords reported insider buying?

The company in question is clinical stage biotechnology company PYC Therapeutics Ltd (ASX: PYC).

According to a change of director's interests notice, the company's non-executive chair, Alan Tribe, just snapped up 50 million shares through an off-market transfer on 17 May. This increased Tribe's holding in PYC Therapeutics to approximately 1.537 billion shares.

The release reveals that the biotech's chair paid a total of $5.25 million for the shares. This equates to an average of 10.5 cents per share. This is in line with where the ASX All Ords stock is currently trading.

Should you invest?

One leading broker that would likely approve of this purchase is Bell Potter.

Earlier this week, the broker initiated coverage on the ASX All Ords stock with a speculative buy rating and 17 cents price target.

Based on its current share price, this implies a potential upside of 62% for investors over the next 12 months.

Commenting on its bullish view, the broker said:

PYC Therapeutics (PYC) is a clinical-stage biotech company harnessing its differentiated RNA drug development platform to treat rare inherited diseases. PYC is actively progressing three drug candidates through clinical development, each of which has first-in-class and/or best-in-class potential. In May 2024, PYC reported highly encouraging first clinical data for its lead drug candidate (called VP-001) in patients with a rare form of blinding eye disease, called retinitis pigmentosa type 11 (RP11).

We initiate coverage of PYC with a speculative BUY recommendation and $0.17 valuation. Pro-forma cash balance was ~$84m as at 31 March 2024, providing runway into 2H CY25 to achieve the above-mentioned Phase 1/2 clinical trial readouts. PYC have multiple shots on goal with three highly promising drug candidates for rare diseases. We also see value in the company's internal platform and potential to continually generate differentiated RNA therapeutics for inherited diseases.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A man sits in contemplation on his sofa looking at his phone as though he has just heard some serious or interesting news.
Technology Shares

Up 60% in two months, is it too late to buy Pro Medicus shares?

Pro Medicus has been delivering solid returns for years. Can the trend continue?

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Why this ASX All Ords stock is jumping 9% today

What has put a rocket under this stock on Friday? Let's find out.

Read more »

A hipster dude leaps in the air with glee, seeing positive news on his tablet.
Healthcare Shares

Which ASX 200 stock is jumping 11% on big news?

Investors are responding very positively to a big announcement.

Read more »

Senior woman using cpap machine to stop choking and snoring from obstructive sleep apnoea with bokeh and morning light background.
Healthcare Shares

Up more than 75% since October 2023 — are ResMed shares a buy, hold or sell?

ResMed shares have surged more than 75% since October 2023, but is it too late to buy? We break down…

Read more »

Stethoscope with a piggy bank in the middle.
Broker Notes

Australian health insurance: Does Macquarie prefer Medibank or NIB shares?

Medibank and NIB shares have both surged in 2025. Here’s what Macquarie expects now.

Read more »

Two brokers analysing stocks.
Healthcare Shares

Why does Macquarie think Fisher & Paykel shares are a buy?

Fisher & Paykel Healthcare Corporation Ltd (ASX: FPH) shares have been on form over the past 12 months. During this…

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Which small cap ASX share is jumping 10% on strong results

Investors have been bidding this stock higher today. But why?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why Macquarie forecasts 30-50% upside for these ASX All Ords healthcare stocks

Macquarie updated its target price on these three ASX All Ords healthcare stocks.

Read more »